iBio, Inc. (IBIO)
| Market Cap | 359.66M |
| Revenue (ttm) | 2.33M |
| Net Income (ttm) | -24.14M |
| Shares Out | 216.01M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $1.65 |
| Previous Close | $1.65 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.55 |
| Day's Range | 1.55 - 1.69 |
| Day's Volume | 10,064,209 |
| 52-Week Range | 1.01 - 7.45 |
These biotech penny stocks pushed up big today; but are they worth it? The post 4 Biotech Penny Stocks That You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...
BRYAN, Texas, May 10, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will repo...
Investors are excited about the company's new coronavirus vaccine program.
Ibio (IBIO) stock is soaring higher on Friday after announcing a next-generation vaccine program to treat the novel coronavirus. The post IBIO Stock: The Covid-19 Vaccine News Sending iBio Soaring Today...
iBio, Inc. (NYSE: IBIO) shares are trading higher after the company provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, I...
iBio Inc (NYSE: IBIO) has provided an update on its IBIO-201 program and reported its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of...
BRYAN, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today provided an update on its I...
A landmark legal settlement should bolster the biotech's growth prospects.
iBio Inc. (NYSE:IBIO) shares gapped higher Wednesday morning after the company announced it successfully resolved its lawsuit with Fraunhofer USA. The resolution confirms iBio's ownership of certain int...
Nemaura Medical Inc. (NASDAQ: NMRD), iBio, Inc. (NYSE: IBIO) and Cocrystal Pharma, Inc. (NASDAQ: COCP) are among the healthcare movers Wednesday. Nemaura Rallies On Receipt of Orders: Nemaura, a medtech...
Ibio (IBIO) stock is on the rise Wednesday after announcing an end to its legal battle with Fraunhofer USA and settlement agreement. The post IBIO Stock: The Big Lawsuit News That Has iBio Shares Rocket...
BRYAN, Texas, May 04, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it has succe...
Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared fir...
Don't bet on iBio for its coronavirus vaccine candidate. It's the company's FastPharming System that could move IBIO stock in the long term.
IBIO stock is not likely to move higher given its huge dilution. I think it is not worth more than 48 cents per share.
BRYAN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it will pa...
These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development. The post 7 Penny Stocks In a Make-or-Break Year appeared first on...
With iBio making key executive-level appointments and recording excellent fiscal stats, IBIO stock's value proposition is hard to ignore. The post Hold iBio Shares as Q2 Highlights Strong Product Catalo...
iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines ...
BRYAN, Tx., Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial resu...
BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will rep...
Ibio (IBIO) stock is on the rise Thursday despite a lack of news coming out today that would result in the movement today. The post IBIO Stock: 5 Things for Investors to Know About iBio Today as Shares ...
If January is a sign of things to come for 2021, traders and investors are going to make a lot of money this year. 4 penny stocks on the move are Anavex Life Sciences (NASDAQ: AVXL), iBio Inc (NYSEMKT: ...
One analyst says investors are underappreciating the biotech's growth prospects.
Shares of IBIO stock are taking off on Friday after an analyst from Cantor Fitzgerald initiated an Overweight rating and $3 price target. The post IBIO Stock Alert: Analyst Call Sends Shares of Pharma i...
Innovation paid off big for investors.
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment ...
BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing of i...
IBIO stock remains volatile as the company continues its focus on a breakthrough product to combat the coronavirus pandemic. The post Be Wary as iBio Seeks a Place in the Vaccine Game appeared first on ...
This can happen when a company holds out its hand for a big chunk of fresh capital.
iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vaccines and th...
Investors bought the Covid-19 hype in IBIO stock. With little progress made, however, reality is setting in, which means the fade should continue.
The IBIO stock price is down, but that doesn't mean the company's in trouble. In fact, the data shows that iBio's fiscal health is improving.
BRYAN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pricing of i...
While its shot at pioneering a novel coronavirus vaccine has passed, iBio and its IBIO stock could benefit from other medical breakthroughs. The post Why iBio Remains Worth a Look In a Post-Pandemic Lan...
BRYAN, Texas, Dec. 07, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced an underwritten ...
Biotech innovator IBIO stock has been tossed around based on iBio's COVID-19 vaccine progress, but its FastPharma tech is the long-term play. The post Biotech Innovator IBIO Is Down, but Not Out for the...
Ibio (IBIO) is seeing shares of IBIO stock soar higher on Wednesday following news of a contract for the biotech company. The post iBio News: Why IBIO Stock Is Soaring 16% Today appeared first on Invest...
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today a...
iBio has a long-standing relationship with the United States defense industry. But that hasn't enough to give IBIO stock a leg up in the Covid-19 race.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of ...
One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibi...
- Methods for Production in iBio's FastPharming® System Foundational to Antifibrotic Development Program - - Methods for Production in iBio's FastPharming® System Foundational to Antifibrotic Developmen...
About IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavir... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NYSEAMERICAN | Ticker Symbol IBIO |
Financial Performance
In 2020, iBio, Inc.'s revenue was $1.64 million, a decrease of -18.83% compared to the previous year's $2.02 million. Losses were -$16.44 million, -6.56% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for iBio, Inc. stock is "Strong Buy" and the 12-month stock price forecast is 2.50.